Abstract
The IGF family of growth factors is believed to play a role in the development and progression of breast cancer. We recently identified an adverse prognostic effect of insulin in breast cancer; we now report prognostic effects of circulating IGFBP's 1 and 3. 512 women with T1-3, N0-1, M0 breast cancer provided fasting blood which was analysed for IGFBP's 1 and 3. Information on body size, diet and traditional prognostic factors and treatment was obtained; women were followed for recurrence and death. IGFBP-1 levels correlated inversely with insulin levels (Spearman r = −0.60, p < 0.0001), reflecting known inhibition of IGFBP-1 gene expression by insulin. Insulin explained 36% of the variance in IGFBP-1 levels. IGFBP-1 levels were also correlated with obesity and diet. Levels of IGFBP-1 significantly predicted distant recurrence and death, hazard ratio (95% CI) for lower versus upper quartile 2.08 (1.20–3.61) and 3.0 (1.45–6.21), respectively. These effects persisted after adjustment for tumor-related variables and treatment but were not independent of insulin levels. High levels of IGFBP-3 predicted distant recurrence (hazard ratio upper v.s. lower quartile 1.8, 95% CI 1.1–3.0) but not death (hazard ratio 1.0, 95% CI 0.5–1.9). The effect on distant recurrence was restricted to postmenopausal women (hazard ratio 3.8, 95% CI 1.6–9.0) and to those with estrogen receptor positive tumors (p = 0.002). Prognostic effects of IGFBP-1 appear related to the known effect of insulin on IGFBP-1 gene expression. The adverse effect of IGFBP-3 on distant recurrence in postmenopausal women with estrogen receptor positive breast cancer should be further investigated.
Similar content being viewed by others
References
Yee D: The insulin-like growth factors and breast cancer revisited. Br Cancer Res Treat 47: 197–199, 1998
Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20: 42–51, 2002
Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ: Insulin and related factors in premenopausal breast cancer risk. Breast Canc Res Treat 47: 111–120, 1998
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396, 1998
Petridou E, Papadiamantas Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D: Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Cont 11: 383–388, 2000
Bruning PF, Van Doorn J, Bonfrer JMG, Van Noord PAH, Korse CM, Linders TC, Hart AAM: Insulin-like growthfactor-binding protein 3 is decreased in early-stage operable breast cancer. Int J Cancer 62: 266–270, 1995
Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS: Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9: 570–573, 1998
Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A: Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88: 828–832, 2000
Agurs-Collins T, Adams-Campbell LL, Kim KS, Cullen KJ: Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women. Cancer Detect Prev 24: 199–206, 2000
Li BD, Khosravi MJ, Berkel HJ, Diamandi A, Dayton MA, Smith M, Yu H: Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 91: 736–739, 2001
Jernstrom H, Barrett-Connor E: Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Womens Health Gend Based Med 8: 1265–1272, 1999
Rasmussen AA, Cullen KJ: Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Canc Res Treat 47: 219–233, 1998
Oh Y: IGF-independent regulation of breast cancer growth by IGF binding proteins. Br Cancer Res Treat 47: 283–293, 1998
Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev 16: 3–34, 1995
Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D: Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem 52: 196–205, 1993
Ng E-H, Ji C-Y, Tan P-H, Lin V, Soo K-C, Lee K-O: Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients. Ann Surg Oncol 5: 194–201, 1998
Holdaway IM, Mason BH, Lethaby AE, Singh V, Harman JE, MacCormick M, Civil ID: Serum levels of insulin-like growth factor binding protein-3 in benign andmalignant breast disease. Aust N Z J Surg 69: 495–500, 1999
Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C-N, Lee AV, Yee D: Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 3: 103–109, 1997
Vadgama JV, Wu Y, Datta G, Khan H, Chillar R: Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57: 330–340, 1999
Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D: Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst 88: 601–606, 1996
Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP: Associations between insulinlike growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer 74: 1242–1247, 1996
Ho G-H, Ji C-Y, Phang B-H, Lee K-O, Soo K-C, Ng E-H: Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: a prospective paired cohort study. Ann Surg Oncol 5: 361–367, 1998
Powell DR, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PDK: Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem 266: 18868–18876, 1991
Lahti EI, Knip M, Laatikainen TJ: Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer 74: 618–624, 1994
Block G, Hartman A, Dresser, Carroll MD, Gannon J, Gardner L: A data based approach to diet questionnaire design and testing. Am J Epidemiol 124: 453–459, 1986
Willett WC, Howe GR, Kushi LH: Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 65: 1220S–1228S, 1997
Busby WH, Snyder DK, Clemmons DR: Radioimmunoassay of a 26,000-Dalton plasma insulin-like growth factor-binding protein: control by nutritional variables. J Clin Endocrinol Metab 67: 1225–1230, 1988
Suikkari A-M, Koivisto VA, Rutanen E-M, Yki-Järvinen H, Karonen S-L, Seppälä M: Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 66: 266–272, 1988
Pratt SE, Pollak MN: Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun 198: 292–297, 1994
Oh Y, Muller HL, Lamson G, Rosenfeld RG: Insulinlike growth factor (IGF)-independent action of IGF-binding protein-3 in Hs 578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268: 14964–14971, 1993
Yee D, Lee AV: Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mamm Gland Biol Neoplasia 5: 107–115, 2000
Barni S, Lissoni P, Brivio F, Fumagalli, Merlini D, Cataldo M, Rovelli F, Tancini G: Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumouri 80: 212–215, 1994
Toropainen E, Lipponen P, Syrjänen K: Expression of insulinlike growth factor I (IGF-I) in female breast cancer as related to established prognostic factors and long-term prognosis. Eur J Cancer 31A: 1443–1448, 1995
Bhatavdekar JM, Patel DD, Karelia NH, Vora HH, Ghosh N, Shah NG, Balar DB, Trivedi SN: Tumor makers in patients with advanced breast cancer as prognosticators: a preliminary study. Breast Canc Res Treat 30: 293–297, 1994
Toropainen EM, Lipponen PK, Syrjänen KJ: Expression of insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis. Anticancer Res 15: 2669–2674, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goodwin, P.J., Ennis, M., Pritchard, K.I. et al. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 74, 65–76 (2002). https://doi.org/10.1023/A:1016075709022
Issue Date:
DOI: https://doi.org/10.1023/A:1016075709022